Control apparatus for automatic stop of engine
    32.
    发明授权
    Control apparatus for automatic stop of engine 有权
    发动机自动停机控制装置

    公开(公告)号:US08793060B2

    公开(公告)日:2014-07-29

    申请号:US13307687

    申请日:2011-11-30

    摘要: A control apparatus controls an automatic stop of an engine mounted on a vehicle so as to automatically stop the engine if a predetermined stop condition is satisfied, the stop condition including a condition that a running speed of the vehicle is a prescribed speed or less. The control apparatus includes a prediction unit and a prohibition unit. The prediction unit predicts whether or not the next automatic stop time of the engine is less than a prescribed time capable of obtaining a fuel saving benefit based on a history of a vehicle stop time or an automatic stop time of the engine. The prohibition unit prohibits the next automatic stop of the engine if the prediction unit predicts that the next automatic stop time of the engine is less than the prescribed time.

    摘要翻译: 控制装置控制安装在车辆上的发动机的自动停止,以便如果满足预定的停止条件则自动停止发动机,停止条件包括车辆行驶速度等于或小于规定速度的条件。 控制装置包括预测单元和禁止单元。 预测单元预测发动机的下一自动停止时间是否小于能够基于发动机的停车时间或自动停止时间的历史来获得省燃料收益的规定时间。 如果预测单元预测发动机的下一个自动停止时间小于规定时间,则禁止单元禁止发动机的下一个自动停止。

    Piperazine compounds and medicinal use thereof
    38.
    发明申请
    Piperazine compounds and medicinal use thereof 审中-公开
    哌嗪类化合物及其医药用途

    公开(公告)号:US20060167014A1

    公开(公告)日:2006-07-27

    申请号:US11298980

    申请日:2005-12-12

    IPC分类号: A61K31/495 C07D241/04

    摘要: The present invention relates to a piperazine compound of the formula wherein R1 and R2 are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4 and R5 are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6 and R7 are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8 and R9 are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

    摘要翻译: 本发明涉及下式的哌嗪化合物其中R 1和R 2各自为氢,卤素,低级烷基,低级烷氧基,氨基,取代的氨基,硝基, 羟基或氰基,R 3,R 4和R 5各自为氢,卤素,低级烷基,低级烷氧基,硝基,氨基,取代的 氨基或羟基,R 6和R 7各自为氢,低级烷基,被卤素取代的低级烷基,芳烷基,酰基或被卤素取代的低级酰基, 8和R 9各自为氢或低级烷基,Y为低级亚烷基等,环A为苯基,嘧啶基,噻唑基,吡啶基,吡唑基或咪唑基,其药学上可接受的盐 和含有这些化合物的药剂。 本发明的化合物具有优异的TNF-α产生抑制作用和/或IL-10产生促进作用,并且由于其没有或显示出仅显着降低对中枢神经系统的作用的表达,所以该化合物是有用的 作为高度安全和优越的TNF-α产生抑制剂和/或IL-10产生促进剂,并且可用作预防或治疗由异常TNF-α产生引起的各种疾病的药剂,可用IL-10固化的疾病,例如 慢性炎性疾病,急性炎性疾病,感染引起的炎性疾病,自身免疫疾病,过敏性疾病和TNF-α介导的疾病。

    Composition containing calcium pantothenate and vitamin
    39.
    发明申请
    Composition containing calcium pantothenate and vitamin 审中-公开
    含有泛酸钙和维生素的组合物

    公开(公告)号:US20060057252A1

    公开(公告)日:2006-03-16

    申请号:US11129352

    申请日:2005-05-16

    IPC分类号: A23L1/30

    摘要: A composition containing calcium pantothenate and at least one kind of vitamin as a mixture of solid state, wherein the calcium pantothenate is crystalline calcium pantothenate obtainable by a method comprising the following steps: (1) the step of mixing crystalline calcium pantothenate and amorphous calcium pantothenate to prepare a homogenous mixture; (2) the step of allowing the homogenous mixture obtained in the aforementioned step (1) to absorb moisture to prepare crystalline calcium pantothenate; and (3) the step of repeating the aforementioned steps (1) and (2) by using the crystalline calcium pantothenate obtained in the aforementioned step (2), and having a ratio (I16.0/I5.1) of the diffraction intensity I16.0 at an diffraction angle (2 θ) of 16° relative to the diffraction intensity I5.1 at an diffraction angle (2 θ) of 5.1° of 1 or more in a powder X-ray diffraction pattern.

    摘要翻译: 一种含有泛酸钙和至少一种作为固体混合物的维生素的组合物,其中泛酸钙是通过包括以下步骤的方法获得的结晶泛酸钙:(1)将结晶泛酸钙和无定形泛酸钙混合的步骤 制备均质混合物; (2)使上述步骤(1)中获得的均匀混合物吸收水分以制备结晶泛酸钙的步骤; 和(3)通过使用在上述步骤(2)中获得的结晶泛酸钙重复上述步骤(1)和(2)的步骤,并且其比例(I 16.0 / 衍射强度I“16.0”的衍射强度I“16”的衍射角相对于衍射强度I <0.05的衍射角(2θ)为16°的衍射角 (2θ)为5.1°,粉末X射线衍射图中为1以上。